Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 3/20 | 0.42 |
| ▸ | BACE1 | P56817 | 11/20 | 0.36 |
| ▸ | APP | P05067 | 6/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8613061 | 1.00 | AKR1B1 (0.42) | AKR1B1BACE1APPCTSDPOLB | |
| SCHEMBL877188 | 0.73 | AKR1B1 (0.46) | AKR1B1BACE1APPCTSD | |
| SCHEMBL876606 | 0.72 | AKR1B1 (0.43) | AKR1B1BACE1APPCTSDPOLB | |
| SCHEMBL891809 | 0.70 | BACE1 (0.39) | AKR1B1BACE1APPCTSDPOLB | |
| SCHEMBL8512036 | 0.68 | BACE1 (0.52) | BACE1CTSD | |
| SCHEMBL9932084 | 0.68 | BACE1 (0.49) | BACE1APPCTSD | |
| SCHEMBL877606 | 0.66 | BACE1 (0.45) | AKR1B1BACE1APPCTSD | |
| SCHEMBL8534440 | 0.66 | BACE1 (0.47) | BACE1APPCTSD | |
| SCHEMBL892490 | 0.65 | BACE1 (0.48) | AKR1B1BACE1CTSD | |
| SCHEMBL875669 | 0.65 | BACE1 (0.77) | BACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | GENENTECH, INC. | 2012-06-21 | — | — | US | disclosed |
| WO-2012071458-A1 | HETEROCYCLIC INHIBITORS OF BETA - SECRETASE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157448-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | AKR1B1 998/4885BACE1 1/4885APP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.